InquiryCervical cancer occurs in the cervix of women and is the fourth most common cancer in women. Almost all cases of cervical cancer (about 99%) are associated with high-risk human papillomavirus (HPV) infection, an extremely common virus transmitted through sexual contact. Although most HPV infections resolve spontaneously and do not cause any symptoms, persistent infection will lead to invasive cervical cancer in women.
Although vaccines have been developed to prevent some of the high-risk types of HPV infections associated with cervical cancer. However, the search for targeted therapies has never stopped. And cervical cancer exhibits a high degree of heterogeneity both among tumors and in the microenvironment, allowing cancer to evolve throughout disease progression, leading to treatment failure. This makes the effective treatment of advanced invasive cervical cancer still challenging.
How the spatial-omics solution we offer can be useful in cervical cancer research
CD Genomics offers spatial-omics-based solutions to help our customers learn more about the genetic, and structural changes in the cells that cause cervical cancer. This leads to the targeted blocking of certain growth factors that contribute to the growth of cervical cancer cells, which helps in some early studies and the development of targeted drugs for patients with advanced cervical cancer.
Figure 1. Workflow of snRNA-seq and Stereo-seq experiments applied to cervical tissues. (Zhi, O., et al., 2021)
What our clients can get
- Bulk sequencing of cervical cancer samples to identify small subpopulations of cancer tissue.
- Access to in situ gene expression profiles to understand cell-to-cell interactions in cervical cancer tissues.
- Dissecting the cellular composition of cervical cancer and characterizing the molecular properties of complex tissues.
- Identify all cell types in the tissue, including rare cell populations.
- Genomic variation analysis (GSVA) of different pathways.
Sample types: freshly collected samples, compatible with FFPE samples and OCT-embedded samples
Technology features and benefits
- Reveals transcriptional variants that may affect prognosis.
- Ability to eliminate differences caused by tumor microenvironment compared to traditional bulk RNA-seq.
- Discover evidence of tumor cell heterogeneity identified by different cervical cancer cell markers and the presence of CSC in tumor samples associated with tumor progression.
- Provides an opportunity to discover new cellular regulators as potential prognostic markers and/or drug targets.
We do it better
Single-cell sequencing and spatial transcriptomics are the latest tools for uncovering tumor cell heterogeneity and microenvironment. CD Genomics offers solutions based on spatial omics technologies that enable our customers to understand how these cervical cancer cell populations and their transcriptomes participate in various pathological settings. We are committed to deciphering the microenvironment of cervical cancer tumors to provide new insights into the treatment of advanced cervical cancer, which may accelerate the elimination of cervical cancer.
Reference
- Zhi, O., et al., (2021). "Single-nucleus RNA Sequencing and Spatial Transcriptomics Reveal the Immunological Microenvironment of Cervical Squamous Cell Carcinoma." bioRxiv. 12(23), 473944.
